L’Oréal USA Settles First Hair Relaxer Cancer Trial
Editors carefully fact-check all Consumer Notice, LLC content for accuracy and quality.
Consumer Notice, LLC has a stringent fact-checking process. It starts with our strict sourcing guidelines.
We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.
Four women who said chemical hair straighteners caused their cancer reached a settlement with L’Oréal USA and several other manufacturers on Nov. 16, ending the first trial before it reached a verdict.
MaryAnne Lindsey, Surenthia Jenkins, Miranda Lofton and Sandra Simpson filed their cases in Cook County, Illinois, in 2023 and 2024. Jury selection began Nov. 9 in Chicago.
Their attorneys said the cases settled for a confidential amount.
Danielle Ward Mason, an attorney for the women, said she hoped the settlement would give her clients a sense of justice.
A L’Oréal spokesperson said consumer health and wellbeing is the company’s top priority. The company remains confident in the safety of its products, including SoftSheen-Carson hair relaxers. L’Oréal has also argued that the research behind the lawsuits does not prove its products caused the plaintiffs’ conditions.
Thousands of Lawsuits Remain
The four women are among thousands who have filed chemical hair straightener lawsuits alleging that years of using relaxers caused uterine, ovarian or other gynecologic cancers. Many of the chemical hair straighteners named in the litigation, including Dark & Lovely and Optimum, have been widely marketed to Black women.
More than 12,700 cases are consolidated in a federal multidistrict litigation (MDL) in Chicago, and others are pending in state courts. Arizona and Minnesota also sued L’Oréal this year, accusing the company of misleading women about product safety.
The first lawsuits followed a 2022 National Institutes of Health study that found women who frequently used straighteners were more than twice as likely to develop uterine cancer. Plaintiffs say endocrine-disrupting chemicals in the products cause this and other health risks.
Expert Rulings Favor Plaintiffs
The settlement comes weeks after key rulings on scientific evidence in the federal MDL. On Oct. 22, U.S. District Judge Mary Rowland declined to exclude testimony from Dr. Cote, an epidemiologist who concluded that chemical hair relaxers can cause uterine and ovarian cancer.
In a Nov. 12 order, Rowland allowed four more plaintiffs’ experts to testify: gynecologic oncologists Dr. Dario Roque and Dr. Sameer Sharma, Dr. Panigrahy and dermatology expert Dr. Brown.
She excluded Dr. Chang, a reproductive endocrinologist she found unqualified to address cancer causation, and dermatologist Dr. Pugliese, who did not adequately explain her methodology. The rulings don’t decide who is right about the science, and manufacturers can still challenge the experts at trial.
Upcoming Bellwether Trials
The first federal bellwether trial is scheduled to begin Sept. 7, 2027. In October, the parties agreed on five bellwether cases brought by Bridget Boatwright, Carrie Chattman, Charlene Fennell, Gloria Ford and Karla Smith, who allege relaxers contributed to their uterine, endometrial or ovarian cancers. The court hasn’t announced which case will be tried first, but Ford’s, which is the only ovarian cancer case, is most likely to be among the last to be tried.
Bellwether verdicts don’t bind other cases, but they help both sides gauge how juries may value claims and often influence settlement talks.
Because the Cook County cases settled before a verdict, no jury has yet weighed the evidence, leaving the September 2027 federal trial as the next major test of how jurors view the science behind the claims.